# Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL

> **NCT06570447** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Diffuse Large B-Cell Lymphoma-Recurrent
- Diffuse Large B-Cell Lymphoma-Refractory

## Interventions

- **DRUG:** Glofitamab
- **DRUG:** Chidamide

## Key facts

- **NCT ID:** NCT06570447
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06570447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06570447, "Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06570447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*